Advertisement

Hemolytic uremic syndrome in a developing country: Consensus guidelines

  • Arvind BaggaEmail author
  • Priyanka Khandelwal
  • Kirtisudha Mishra
  • Ranjeet Thergaonkar
  • Anil Vasudevan
  • Jyoti Sharma
  • Saroj Kumar Patnaik
  • Aditi Sinha
  • Sidharth Sethi
  • Pankaj Hari
  • Marie-Agnes Dragon-Durey
  • on behalf of the Indian Society of Pediatric Nephrology
Consensus Conference

Abstract

Background

Hemolytic uremic syndrome (HUS) is a leading cause of acute kidney injury in children. Although international guidelines emphasize comprehensive evaluation and treatment with eculizumab, access to diagnostic and therapeutic facilities is limited in most developing countries. The burden of Shiga toxin-associated HUS in India is unclear; school-going children show high prevalence of anti-factor H (FH) antibodies. The aim of the consensus meeting was to formulate guidelines for the diagnosis and management of HUS in children, specific to the needs of the country.

Methods

Four workgroups performed literature review and graded research studies addressing (i) investigations, biopsy, genetics, and differential diagnosis; (ii) Shiga toxin, pneumococcal, and infection-associated HUS; (iii) atypical HUS; and (iv) complement blockade. Consensus statements developed by the workgroups were discussed during a consensus meeting in March 2017.

Results

An algorithm for classification and evaluation was developed. The management of Shiga toxin-associated HUS is supportive; prompt plasma exchanges (PEX) is the chief therapy in patients with atypical HUS. Experts recommend that patients with anti-FH-associated HUS be managed with a combination of PEX and immunosuppressive medications. Indications for eculizumab include incomplete remission with plasma therapy, life-threatening features, complications of PEX or vascular access, inherited defects in complement regulation, and recurrence of HUS in allografts. Priorities for capacity building in regional and national laboratories are highlighted.

Conclusions

Limited diagnostic capabilities and lack of access to eculizumab prevent the implementation of international guidelines for HUS in most developing countries. We propose practice guidelines for India, which will perhaps be applicable to other developing countries.

Keywords

Anti-factor H antibodies Complement Plasma exchange Thrombotic microangiopathy 

Notes

Acknowledgments

Funding support for collaborative research studies and consensus development by Indo-French Centre for the Promotion of Advanced Research (CEFIPRA) [IFC/A/4703-1/2015/1562; IFC/Network 1/2185]; Department of Biotechnology, Government of India [BT/PR14651/MED/30/566/2010]; Indian Council of Medical Research [Advanced Centre for Research in Pediatric Kidney Diseases; 5/7/1090/2013-RHN]; Department of Science and Technology, Government of India [EMR12016/002781]; and All India Institute of Medical Sciences, New Delhi [A-386].

Working group members

Ranjeet Thergaonkar, Vishakapatnam (Group Chair)

Kirtisudha Mishra, New Delhi (Group Chair)

Sushmita Banerjee, Kolkata

Kamran Afzal, Aligarh

Sriram Krishnamurthy, Puducherry

Girish Bhatt, Bhopal

Manish Kumar, New Delhi

Mamta Puraswani, New Delhi

Anil Vasudevan, Bangalore (Group Chair)

Jyoti Sharma, Pune (Group Chair)

Indira Agarwal, Vellore

OP Mishra, Varanasi

Karalanglin Tiewsoh, Chandigarh

Aditi Sinha, New Delhi (Group Chair)

Saroj K Patnaik, New Delhi (Group Chair)

Amarjeet Mehta, Jaipur (President, ISPN)

Susan Uthup, Thiruvanthapuram

Rajiv Sinha, Kolkata

Sudha Ekambaram, Chennai

Pankaj Hari, New Delhi (Group Chair)

Sidharth Sethi, Gurugram (Group Chair and Secretary, ISPN)

Abhijeet Saha, New Delhi

Swati Bhardwaj, New Delhi

Priyanka Khandelwal, New Delhi (Rapporteur)

Arvind Bagga, New Delhi (Coordinator)

Experts

Marie-Agnes Dragon-Durey, Hopital Europeen Georges Pompidou, INSERM UMRS 1138, Paris, France

Amit K Dinda, All India Institute of Medical Sciences, New Delhi

Neelam Taneja, Postgraduate Institute of Medical Education and Research, Chandigarh

Supplementary material

467_2019_4233_MOESM1_ESM.docx (27 kb)
ESM 1 (DOCX 27 kb)

References

  1. 1.
    Srivastava RN, Moudgil A, Bagga A, Vasudev AS (1991) Hemolytic uremic syndrome in children in northern India. Pediatr Nephrol 5:284–288CrossRefPubMedGoogle Scholar
  2. 2.
    Kumar A, Taneja N, Sharma M (2014) An epidemiological and environmental study of Shiga toxin-producing Escherichia coli in India. Foodborne Pathog Dis 11:439–446CrossRefPubMedGoogle Scholar
  3. 3.
    Purwar S, Roy S, Metgud S (2016) Non-O157:H7 Shiga toxin producing diarrhoeagenic Escherichia coli (STEC) in southern India: a tinderbox for starting epidemic. J Clin Diagn Res 10:DC11–DC15CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hegde A, Ballal M, Shenoy S (2012) Detection of diarrheagenic Escherichia coli by multiplex PCR. Indian J Med Microbiol 30:279–284CrossRefPubMedGoogle Scholar
  5. 5.
    Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, Saini H, Kotresh ST, Ali U, Bhatia D, Ohri A, Kumar M, Agarwal I, Gulati S, Anand K, Vijayakumar M, Sinha R, Sethi S, Salmona M, George A, Bal V, Singh G, Dinda AK, Hari P, Rath S, Dragon-Durey MA, Bagga A, Indian HUS Registry (2014) Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 85:1151–1160CrossRefPubMedGoogle Scholar
  6. 6.
    Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y, Kaname S, Okada H, Sato W, Yasuda T, Yoshida Y, Fujimura Y, Hattori M, Kagami S (2014) Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Pediatr Int 56:1–5CrossRefPubMedGoogle Scholar
  7. 7.
    Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S, Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan (2016) Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 20:536–543CrossRefPubMedGoogle Scholar
  8. 8.
    Cheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO, Koo JR, Park Y, Park YS, Shin JI, Yoo KH, Oh D (2016) Clinical practice guidelines for the management of atypical hemolytic uremic syndrome in Korea. J Korean Med Sci 31:1516–1528CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB, European Paediatric Study Group for HUS (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24:687–696CrossRefPubMedGoogle Scholar
  10. 10.
    Taylor CM, Machin S, Wigmore SJ, Goodship TH, on behalf of a working party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society (2010) Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 148:37–47CrossRefPubMedGoogle Scholar
  11. 11.
    Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyo JM, Macia M, Mendizabal S, Praga M, Roman E, Torra R, Valdes F, Vilalta R, Rodriguez de Cordoba S (2015) An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 35:421–447CrossRefPubMedGoogle Scholar
  12. 12.
    Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD (2018) Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Intern Med J 48:624–636CrossRefPubMedGoogle Scholar
  13. 13.
    Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Fremeaux-Bacchi V, HUS International (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15–39CrossRefPubMedGoogle Scholar
  14. 14.
    Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ, Grade Working Group (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2:1–138CrossRefGoogle Scholar
  16. 16.
    Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, International Registry of Recurrent and Familial HUS/TTP (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267–1279CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Daram SR, Philipneri M, Puri N, Bastani B (2005) Thrombotic thrombocytopenic purpura without schistocytes on the peripheral blood smear. South Med J 98:392–395CrossRefPubMedGoogle Scholar
  18. 18.
    Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C (2017) Haemolytic uraemic syndrome. Lancet 390:681–696CrossRefPubMedGoogle Scholar
  19. 19.
    Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschenes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554–562CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Di Nisio M, Baudo F, Cosmi B, D’Angelo A, De Gasperi A, Malato A, Schiavoni M, Squizzato A, Italian Society for Haemostasis and Thrombosis (2012) Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 129:e177–e184CrossRefPubMedGoogle Scholar
  21. 21.
    Bakhtiari K, Meijers JC, de Jonge E, Levi M (2004) Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 32:2416–2421CrossRefPubMedGoogle Scholar
  22. 22.
    Joly BS, Stepanian A, Leblanc T, Hajage D, Chambost H, Harambat J, Fouyssac F, Guigonis V, Leverger G, Ulinski T, Kwon T, Loirat C, Coppo P, Veyradier A, French Reference Center for Thrombotic Microangiopathies (2016) Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematol 3:e537–e546CrossRefPubMedGoogle Scholar
  23. 23.
    Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodriguez de Cordoba S, Roumenina LT, Sethi S, Smith RJ, Conference Participants (2017) Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 91:539–551CrossRefPubMedGoogle Scholar
  24. 24.
    Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lammle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H, International Working Group for Thrombotic Thrombocytopenic Purpura (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15:312–322CrossRefPubMedGoogle Scholar
  25. 25.
    Cataland SR, Wu HM (2013) Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies. Eur J Intern Med 24:486–491CrossRefPubMedGoogle Scholar
  26. 26.
    Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, Poullin P, Malot S, Vanhille P, Azoulay E, Galicier L, Lemiale V, Mira JP, Ridel C, Rondeau E, Pourrat J, Girault S, Bordessoule D, Saheb S, Ramakers M, Hamidou M, Vernant JP, Guidet B, Wolf M, Veyradier A, French Reference Center for Thrombotic Microangiopathies (2010) Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One 5:e10208CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ, British Committee for Standards in Haematology (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 158:323–335CrossRefPubMedGoogle Scholar
  28. 28.
    Sinha A, Singh G, Bhat AS, Mohapatra S, Gulati A, Hari P, Samantaray JC, Dinda AK, Agarwal SK, Bagga A (2013) Thrombotic microangiopathy and acute kidney injury following vivax malaria. Clin Exp Nephrol 17:66–72CrossRefPubMedGoogle Scholar
  29. 29.
    Bhatia D, Khandelwal P, Sinha A, Hari P, Cheong HI, Bagga A (2015) Incomplete penetrance of CD46 mutation causing familial atypical hemolytic uremic syndrome. Pediatr Nephrol 30:2215–2220CrossRefPubMedGoogle Scholar
  30. 30.
    Muthuppalaniappan VM, Rajakariar R, Blunden MJ (2018) Leptospirosis presenting as haemolytic uraemic syndrome: a case report. BMC Nephrol 19:20CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Gould LH, Bopp C, Strockbine N, Atkinson R, Baselski V, Body B, Carey R, Crandall C, Hurd S, Kaplan R, Neill M, Shea S, Somsel P, Tobin-D'Angelo M, Griffin PM, Gerner-Smidt P, Centers for Disease Control and Prevention (CDC) (2009) Recommendations for diagnosis of Shiga toxin-producing Escherichia coli infections by clinical laboratories. MMWR Recomm Rep 58:1–14PubMedGoogle Scholar
  32. 32.
    Igarashi T, Ito S, Sako M, Saitoh A, Hataya H, Mizuguchi M, Morishima T, Ohnishi K, Kawamura N, Kitayama H, Ashida A, Kaname S, Taneichi H, Tang J, Ohnishi M, Study group for establishing guidelines for the diagnosis and therapy of hemolytic uremic syndrome (2014) Guidelines for the management and investigation of hemolytic uremic syndrome. Clin Exp Nephrol 18:525–557CrossRefPubMedGoogle Scholar
  33. 33.
    Qin X, Klein EJ, Galanakis E, Thomas AA, Stapp JR, Rich S, Buccat AM, Tarr PI (2015) Real-time PCR assay for detection and differentiation of Shiga toxin-producing Escherichia coli from clinical samples. J Clin Microbiol 53:2148–2153CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Wijnsma KL, van Bommel SA, van der Velden T, Volokhina E, Schreuder MF, van den Heuvel LP, van de Kar NC (2016) Fecal diagnostics in combination with serology: best test to establish STEC-HUS. Pediatr Nephrol 31:2163–2170CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Taneja N, Mewara A (2016) Shigellosis: epidemiology in India. Indian J Med Res 143:565–576CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Tarr PI, Neill MA, Clausen CR, Watkins SL, Christie DL, Hickman RO (1990) Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology. J Infect Dis 162:553–556CrossRefPubMedGoogle Scholar
  37. 37.
    Vonberg RP, Hohle M, Aepfelbacher M, Bange FC, Belmar Campos C, Claussen K, Christner M, Cramer JP, Haller H, Hornef M, Fickenscher H, Fraedrich K, Knobloch JK, Kuhbacher T, Manns MP, Nitschke M, Peters G, Pulz M, Rohde H, Roseland RT, Sayk F, Schaumburg F, Schocklmann HO, Schubert S, Solbach W, Karch H, Suerbaum S (2013) Duration of fecal shedding of Shiga toxin-producing Escherichia coli O104:H4 in patients infected during the 2011 outbreak in Germany: a multicenter study. Clin Infect Dis 56:1132–1140CrossRefPubMedGoogle Scholar
  38. 38.
    Bell BP, Griffin PM, Lozano P, Christie DL, Kobayashi JM, Tarr PI (1997) Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 100:E12CrossRefPubMedGoogle Scholar
  39. 39.
    Mody RK, Gu W, Griffin PM, Jones TF, Rounds J, Shiferaw B, Tobin-D'Angelo M, Smith G, Spina N, Hurd S, Lathrop S, Palmer A, Boothe E, Luna-Gierke RE, Hoekstra RM (2015) Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death. J Pediatr 166:1022–1029CrossRefPubMedGoogle Scholar
  40. 40.
    Loupiac A, Elayan A, Cailliez M, Adra AL, Decramer S, Thouret MC, Harambat J, Guigonis V (2013) Diagnosis of Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Infect Dis J 32:1045–1049CrossRefPubMedGoogle Scholar
  41. 41.
    Spinale JM, Ruebner RL, Kaplan BS, Copelovitch L (2013) Update on Streptococcus pneumoniae associated hemolytic uremic syndrome. Curr Opin Pediatr 25:203–208CrossRefPubMedGoogle Scholar
  42. 42.
    Manoharan A, Manchanda V, Balasubramanian S, Lalwani S, Modak M, Bai S, Vijayan A, Shet A, Nagaraj S, Karande S, Nataraj G, Yewale VN, Joshi SA, Iyer RN, Santosham M, Kahn GD, Knoll MD, Alliance for Surveillance of Invasive Pneumococci Study Group (2017) Invasive pneumococcal disease in children aged younger than 5 years in India: a surveillance study. Lancet Infect Dis 17:305–312CrossRefPubMedGoogle Scholar
  43. 43.
    Beck BB, van Spronsen F, Diepstra A, Berger RM, Komhoff M (2017) Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity. Pediatr Nephrol 32:733–741CrossRefPubMedGoogle Scholar
  44. 44.
    Huemer M, Diodato D, Schwahn B, Schiff M, Bandeira A, Benoist JF, Burlina A, Cerone R, Couce ML, Garcia-Cazorla A, la Marca G, Pasquini E, Vilarinho L, Weisfeld-Adams JD, Kozich V, Blom H, Baumgartner MR, Dionisi-Vici C (2017) Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis 40:21–48CrossRefPubMedGoogle Scholar
  45. 45.
    Kavanagh D, Goodship TH (2011) Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematology Am Soc Hematol Educ Program 2011:15–20CrossRefPubMedGoogle Scholar
  46. 46.
    Bouts AH, Roofthooft MT, Salomons GS, Davin JC (2010) CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency. Pediatr Nephrol 25:2547–2548CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, Licht C (2014) Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 40:444–464CrossRefPubMedGoogle Scholar
  48. 48.
    Thergaonkar RW, Narang A, Gurjar BS, Tiwari P, Puraswani M, Saini H, Sinha A, Varma B, Mukerji M, Hari P, Bagga A (2018) Targeted exome sequencing in anti-factor H antibody negative HUS reveals multiple variations. Clin Exp Nephrol 22:653–660CrossRefPubMedGoogle Scholar
  49. 49.
    Bu F, Zhang Y, Wang K, Borsa NG, Jones MB, Taylor AO, Takanami E, Meyer NC, Frees K, Thomas CP, Nester C, Smith RJH (2018) Genetic analysis of 400 patients refines understanding and implicates a new gene in atypical hemolytic uremic syndrome. J Am Soc Nephrol 29:2809–2819CrossRefPubMedGoogle Scholar
  50. 50.
    Challis RC, Ring T, Xu Y, Wong EK, Flossmann O, Roberts IS, Ahmed S, Wetherall M, Salkus G, Brocklebank V, Fester J, Strain L, Wilson V, Wood KM, Marchbank KJ, Santibanez-Koref M, Goodship TH, Kavanagh D (2017) Thrombotic microangiopathy in inverted formin 2-mediated renal disease. J Am Soc Nephrol 28:1084–1091CrossRefPubMedGoogle Scholar
  51. 51.
    Osborne AJ, Breno M, Borsa NG, Bu F, Fremeaux-Bacchi V, Gale DP, van den Heuvel LP, Kavanagh D, Noris M, Pinto S, Rallapalli PM, Remuzzi G, Rodriguez de Cordoba S, Ruiz A, Smith RJH, Vieira-Martins P, Volokhina E, Wilson V, Goodship THJ, Perkins SJ (2018) Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy. J Immunol 200:2464–2478CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Khandelwal P, Birla S, Bhatia D, Puraswani M, Saini H, Sinha A, Hari P, Sharma A, Bagga A (2018) Mutations in membrane cofactor protein (CD46) gene in Indian children with hemolytic uremic syndrome. Clin Kidney J 11:198–203CrossRefPubMedGoogle Scholar
  53. 53.
    Fremeaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, Arzouk N, Cleper R, Francois M, Guest G, Pourrat J, Seligman R, Fridman WH, Loirat C, Atkinson JP (2006) Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 17:2017–2025CrossRefPubMedGoogle Scholar
  54. 54.
    Durey MA, Sinha A, Togarsimalemath SK, Bagga A (2016) Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 12:563–578CrossRefPubMedGoogle Scholar
  55. 55.
    Watson R, Lindner S, Bordereau P, Hunze EM, Tak F, Ngo S, Zipfel PF, Skerka C, Dragon-Durey MA, Marchbank KJ (2014) Standardisation of the factor H autoantibody assay. Immunobiology 219:9–16CrossRefPubMedGoogle Scholar
  56. 56.
    Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M, European Working Party on Complement Genetics in Renal Diseases (2013) Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24:475–486CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Holmes LV, Strain L, Staniforth SJ, Moore I, Marchbank K, Kavanagh D, Goodship JA, Cordell HJ, Goodship TH (2013) Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32. PLoS One 8:e60352CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Gurjar BS, Manikanta Sriharsha T, Bhasym A, Prabhu S, Puraswani M, Khandelwal P, Saini H, Saini S, Verma AK, Chatterjee P, Guchhait P, Bal V, George A, Rath S, Sahu A, Sharma A, Hari P, Sinha A, Bagga A (2018) Characterization of genetic predisposition and autoantibody profile in atypical haemolytic-uraemic syndrome. Immunology.  https://doi.org/10.1111/imm.12916
  59. 59.
    Khandelwal P, Faruq M, Puraswani M, Sinha A, Bagga A (2018) Coexisting variations in complement regulatory genes increase risk of relapse in anti-Factor H antibody associated atypical hemolytic uremic syndrome. https://www.asn-online.org/education/kidneyweek/2018/program-abstract.aspx?controlId=3024369
  60. 60.
    Grisaru S, Xie J, Samuel S, Hartling L, Tarr PI, Schnadower D, Freedman SB, Alberta Provincial Pediatric Enteric Infection Team (2017) Associations between hydration status, intravenous fluid administration, and outcomes of patients infected with Shiga toxin-producing Escherichia coli: a systematic review and meta-analysis. JAMA Pediatr 171:68–76CrossRefPubMedGoogle Scholar
  61. 61.
    Ake JA, Jelacic S, Ciol MA, Watkins SL, Murray KF, Christie DL, Klein EJ, Tarr PI (2005) Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 115:e673–e680CrossRefPubMedGoogle Scholar
  62. 62.
    Ardissino G, Dacco V, Testa S, Civitillo CF, Tel F, Possenti I, Belingheri M, Castorina P, Bolsa-Ghiringhelli N, Tedeschi S, Paglialonga F, Salardi S, Consonni D, Zoia E, Salice P, Chidini G (2015) Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome. Pediatr Nephrol 30:345–352CrossRefPubMedGoogle Scholar
  63. 63.
    Ardissino G, Tel F, Possenti I, Testa S, Consonni D, Paglialonga F, Salardi S, Borsa-Ghiringhelli N, Salice P, Tedeschi S, Castorina P, Colombo RM, Arghittu M, Daprai L, Monzani A, Tozzoli R, Brigotti M, Torresani E (2016) Early volume expansion and outcomes of hemolytic uremic syndrome. Pediatrics 137Google Scholar
  64. 64.
    Hickey CA, Beattie TJ, Cowieson J, Miyashita Y, Strife CF, Frem JC, Peterson JM, Butani L, Jones DP, Havens PL, Patel HP, Wong CS, Andreoli SP, Rothbaum RJ, Beck AM, Tarr PI (2011) Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 165:884–889CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Balestracci A, Martin SM, Toledo I, Alvarado C, Wainsztein RE (2012) Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children. Pediatr Nephrol 27:1407–1410CrossRefPubMedGoogle Scholar
  66. 66.
    WHO (2017) The selection and use of essential medicines. www.who.int/medicines/publications/essentialmedicines/en/
  67. 67.
    Williams PCM, Berkley JA (2018) Guidelines for the treatment of dysentery (shigellosis): a systematic review of the evidence. Paediatr Int Child Health 38:S50–S65CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Agger M, Scheutz F, Villumsen S, Mølbak K, Petersen AM (2015) Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposal. J Antimicrob Chemother 70:2440–2446CrossRefPubMedGoogle Scholar
  69. 69.
    Freedman SB, Xie J, Neufeld MS, Hamilton WL, Hartling L, Tarr PI, Alberta Provincial Pediatric Enteric Infection T, Nettel-Aguirre A, Chuck A, Lee B, Johnson D, Currie G, Talbot J, Jiang J, Dickinson J, Kellner J, MacDonald J, Svenson L, Chui L, Louie M, Lavoie M, Eltorki M, Vanderkooi O, Tellier R, Ali S, Drews S, Graham T, Pang XL (2016) Shiga toxin-producing Escherichia coli infection, antibiotics, and risk of developing hemolytic uremic syndrome: a meta-analysis. Clin Infect Dis 62:1251–1258CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Safdar N, Said A, Gangnon RE, Maki DG (2002) Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 288:996–1001CrossRefPubMedGoogle Scholar
  71. 71.
    Rosales A, Hofer J, Zimmerhackl L-B, Jungraithmayr TC, Riedl M, Giner T, Strasak A, Orth-Höller D, Würzner R, Karch H (2012) Need for long-term follow-up in enterohemorrhagic Escherichia coli–associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 54:1413–1421CrossRefPubMedGoogle Scholar
  72. 72.
    Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenmuller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer TN, Michael C, Munte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump LC, Samuelsson O, Sayk F, Schmidt BM, Schnatter S, Schocklmann H, Schreiber S, von Seydewitz CU, Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, Wellhoner P, Wiesner M, Zeissig S, Buning J, Schiffer M, Kuehbacher T, EHEC-HUS consortium (2012) Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 345:e4565CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Corogeanu D, Willmes R, Wolke M, Plum G, Utermohlen O, Kronke M (2012) Therapeutic concentrations of antibiotics inhibit Shiga toxin release from enterohemorrhagic E. coli O104:H4 from the 2011 German outbreak. BMC Microbiol 12:160CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Nitschke M, Sayk F, Hartel C, Roseland RT, Hauswaldt S, Steinhoff J, Fellermann K, Derad I, Wellhoner P, Buning J, Tiemer B, Katalinic A, Rupp J, Lehnert H, Solbach W, Knobloch JK (2012) Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 307:1046–1052CrossRefPubMedGoogle Scholar
  75. 75.
    Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH (2016) Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 31:149–162PubMedGoogle Scholar
  76. 76.
    Rizzoni G, Claris-Appiani A, Edefonti A, Facchin P, Franchini F, Gusmano R, Imbasciati E, Pavanello L, Perfumo F, Remuzzi G (1988) Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 112:284–290CrossRefPubMedGoogle Scholar
  77. 77.
    Loirat C, Sonsino E, Hinglais N, Jais JP, Landais P, Fermanian J (1988) Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol 2:279–285CrossRefPubMedGoogle Scholar
  78. 78.
    Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, Busch V, Ries W, Mitzner S, Mees S, Stracke S, Nurnberger J, Gerke P, Wiesner M, Sucke B, Abu-Tair M, Kribben A, Klause N, Schindler R, Merkel F, Schnatter S, Dorresteijn EM, Samuelsson O, Brunkhorst R, Collaborators of the DGfN STEC-HUS registry (2012) Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 27:3807–3815CrossRefPubMedGoogle Scholar
  79. 79.
    Loos S, Ahlenstiel T, Kranz B, Staude H, Pape L, Hartel C, Vester U, Buchtala L, Benz K, Hoppe B, Beringer O, Krause M, Muller D, Pohl M, Lemke J, Hillebrand G, Kreuzer M, Konig J, Wigger M, Konrad M, Haffner D, Oh J, Kemper MJ (2012) An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 55:753–759CrossRefPubMedGoogle Scholar
  80. 80.
    Dundas S, Murphy J, Soutar RL, Jones GA, Hutchinson SJ, Todd WT (1999) Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 354:1327–1330CrossRefPubMedGoogle Scholar
  81. 81.
    Nathanson S, Kwon T, Elmaleh M, Charbit M, Launay EA, Harambat J, Brun M, Ranchin B, Bandin F, Cloarec S, Bourdat-Michel G, Pietrement C, Champion G, Ulinski T, Deschenes G (2010) Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 5:1218–1228CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Keenswijk W, Raes A, De Clerck M, Vande Walle J (2018) Is plasma exchange efficacious in Shiga toxin-associated hemolytic uremic syndrome? A narrative review of current evidence. Ther Apher Dial.  https://doi.org/10.1111/1744-9987.12768
  83. 83.
    Bruyand M, Mariani-Kurkdjian P, Gouali M, de Valk H, King LA, Le Hello S, Bonacorsi S, Loirat C (2018) Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Med Mal Infect 48:167–174CrossRefPubMedGoogle Scholar
  84. 84.
    Pape L, Hartmann H, Bange FC, Suerbaum S, Bueltmann E, Ahlenstiel-Grunow T (2015) Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine (Baltimore) 94:e1000CrossRefPubMedGoogle Scholar
  85. 85.
    Delmas Y, Vendrely B, Clouzeau B, Bachir H, Bui HN, Lacraz A, Helou S, Bordes C, Reffet A, Llanas B, Skopinski S, Rolland P, Gruson D, Combe C (2014) Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 29:565–572CrossRefPubMedGoogle Scholar
  86. 86.
    Percheron L, Gramada R, Tellier S, Salomon R, Harambat J, Llanas B, Fila M, Allain-Launay E, Lapeyraque AL, Leroy V, Adra AL, Berard E, Bourdat-Michel G, Chehade H, Eckart P, Merieau E, Pietrement C, Sellier-Leclerc AL, Fremeaux-Bacchi V, Dimeglio C, Garnier A (2018) Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study. Pediatr Nephrol 33:1385–1394CrossRefPubMedGoogle Scholar
  87. 87.
    Michael M, Elliott EJ, Ridley GF, Hodson EM, Craig JC (2009) Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev:CD003595Google Scholar
  88. 88.
    Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181CrossRefPubMedGoogle Scholar
  89. 89.
    Hafer C, Golla P, Gericke M, Eden G, Beutel G, Schmidt JJ, Schmidt BM, De Reys S, Kielstein JT (2016) Membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study. Int Urol Nephrol 48:133–138CrossRefPubMedGoogle Scholar
  90. 90.
    Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Frieling M, Karpman D, Landau D, Langman C, Licht C, Pecoraro C, Riedl M, Siomou E, van de Kar N, Walle JV, Loirat C, Taylor CM (2014) An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol 29:1967–1978CrossRefPubMedGoogle Scholar
  91. 91.
    Paglialonga F, Schmitt CP, Shroff R, Vondrak K, Aufricht C, Watson AR, Ariceta G, Fischbach M, Klaus G, Holtta T, Bakkaloglu SA, Zurowska A, Jankauskiene A, Vande Walle J, Schaefer B, Wright E, Connell R, Edefonti A (2015) Indications, technique, and outcome of therapeutic apheresis in European pediatric nephrology units. Pediatr Nephrol 30:103–111CrossRefPubMedGoogle Scholar
  92. 92.
    Davin JC, Groothoff J, Gracchi V, Bouts A (2011) Long-term renal function under plasma exchange in atypical hemolytic uremic syndrome. Pediatr Nephrol 26:1915–1916CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844–1859CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provot F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM (2016) Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68:84–93CrossRefPubMedGoogle Scholar
  95. 95.
    Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87:1061–1073CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701–711CrossRefPubMedGoogle Scholar
  97. 97.
    Fakhouri F, Loirat C (2018) Anticomplement treatment in atypical and typical hemolytic uremic syndrome. Semin Hematol 55:150–158CrossRefPubMedGoogle Scholar
  98. 98.
    Azukaitis K, Simkova E, Majid MA, Galiano M, Benz K, Amann K, Bockmeyer C, Gajjar R, Meyers KE, Cheong HI, Lange-Sperandio B, Jungraithmayr T, Fremeaux-Bacchi V, Bergmann C, Bereczki C, Miklaszewska M, Csuka D, Prohaszka Z, Gipson P, Sampson MG, Lemaire M, Schaefer F (2017) The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol kinase epsilon. J Am Soc Nephrol 28:3066–3075CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Malina M, Gulati A, Bagga A, Majid MA, Simkova E, Schaefer F (2013) Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics 131:e331–e335CrossRefPubMedGoogle Scholar
  100. 100.
    Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M (2012) Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis 59:707–710CrossRefPubMedGoogle Scholar
  101. 101.
    Ardissino G, Tel F, Testa S, Marzano AV, Lazzari R, Salardi S, Edefonti A (2014) Skin involvement in atypical hemolytic uremic syndrome. Am J Kidney Dis 63:652–655CrossRefPubMedGoogle Scholar
  102. 102.
    Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R (2018) Atypical hemolytic uremic syndrome: a meta-analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens. Ther Apher Dial 22:178–188CrossRefPubMedGoogle Scholar
  103. 103.
    Gulleroglu K, Fidan K, Hancer VS, Bayrakci U, Baskin E, Soylemezoglu O (2013) Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 28:827–830CrossRefPubMedGoogle Scholar
  104. 104.
    Hu H, Nagra A, Haq MR, Gilbert RD (2014) Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement. Pediatr Nephrol 29:1103–1106CrossRefPubMedGoogle Scholar
  105. 105.
    Williams ME, Balogun RA (2014) Principles of separation: indications and therapeutic targets for plasma exchange. Clin J Am Soc Nephrol 9:181–190CrossRefPubMedGoogle Scholar
  106. 106.
    Khandelwal P, Gupta A, Sinha A, Saini S, Hari P, Dragon Durey MA, Bagga A (2015) Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome. Pediatr Nephrol 30:451–457CrossRefPubMedGoogle Scholar
  107. 107.
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150CrossRefGoogle Scholar
  108. 108.
    Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F, Cassuto E, Loirat C, Rondeau E, Delahousse M, Fremeaux-Bacchi V (2013) Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 13:663–675CrossRefPubMedGoogle Scholar
  109. 109.
    Bacchetta J, Cochat P (2015) Primary disease recurrence-effects on paediatric renal transplantation outcomes. Nat Rev Nephrol 11:371–384CrossRefPubMedGoogle Scholar
  110. 110.
    Khandelwal P, Sinha A, Hari P, Bansal VK, Dinda AK, Bagga A (2014) Outcomes of renal transplant in patients with anti-complement factor H antibody-associated hemolytic uremic syndrome. Pediatr Transplant 18:E134–E139CrossRefPubMedGoogle Scholar

Copyright information

© IPNA 2019

Authors and Affiliations

  • Arvind Bagga
    • 1
    Email author
  • Priyanka Khandelwal
    • 1
  • Kirtisudha Mishra
    • 2
  • Ranjeet Thergaonkar
    • 3
  • Anil Vasudevan
    • 4
  • Jyoti Sharma
    • 5
  • Saroj Kumar Patnaik
    • 6
  • Aditi Sinha
    • 1
  • Sidharth Sethi
    • 7
  • Pankaj Hari
    • 1
  • Marie-Agnes Dragon-Durey
    • 8
  • on behalf of the Indian Society of Pediatric Nephrology
  1. 1.Division of Nephrology, Department of PediatricsAll India Institute of Medical SciencesNew DelhiIndia
  2. 2.Department of PediatricsChacha Nehru Bal ChikitsalyaNew DelhiIndia
  3. 3.Department of PediatricsIndian Naval Hospital Ship, KalyaniVisakhapatnamIndia
  4. 4.Department of Pediatric NephrologySt. Johns Medical College and HospitalBengaluruIndia
  5. 5.Department of PediatricsKEM HospitalPuneIndia
  6. 6.Department of PediatricsArmy Hospital Research & ReferralNew DelhiIndia
  7. 7.Department of NephrologyMedanta HospitalNew DelhiIndia
  8. 8.Laboratory of Immunology, Hopital Europeen Georges Pompidou, INSERM UMRS 1138Paris Descartes UniversityParisFrance

Personalised recommendations